MCIA
SGMO

Mountain Capital Investment Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Mountain Capital Investment Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500
Closed -$8K – 357
2017
Q3 		$8K Hold
500
– – 0.01% 300
2017
Q2 		$4K Buy
+500
New +$3.21K ﹤0.01% 398

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mountain Capital Investment Advisors's SGMO Position: Q4 2017 in Review

Mountain Capital Investment Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 500 shares — an estimated $8K sold.

Mountain Capital Investment Advisors first reported a position in SGMO in Q2 2017 and held it in 2 quarters. The position peaked at $8K in Q3 2017. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • Mountain Capital Investment Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • Mountain Capital Investment Advisors sold 500 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $8K.
  • Mountain Capital Investment Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 2 quarters.
  • Mountain Capital Investment Advisors's SANGAMO THERAPEUTICS INC position peaked at $8K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on Mountain Capital Investment Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.